Zobrazeno 1 - 10
of 698
pro vyhledávání: '"Donald A, Berry"'
Autor:
Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer, Donald A. Berry
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-9 (2022)
Abstract Background Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-month phase 2 proof-of-c
Externí odkaz:
https://doaj.org/article/4ce48fe8ab7742dd95eb4cc183c3ed7b
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Henry Hiep Vo, Siqing Fu, David S. Hong, Daniel D. Karp, Sarina Piha-Paul, Vivek Subbiah, Filip Janku, Aung Naing, Timothy A. Yap, Jordi Rodon, Jaffer A. Ajani, Carrie Cartwright, Amber Johnson, I-Wen Song, Jennifer Beck, Michael Kahle, Graciela M. Nogueras-Gonzalez, Vincent Miller, Calvin Chao, David J. Vining, Donald A. Berry, Funda Meric-Bernstam, Apostolia-Maria Tsimberidou
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-12 (2022)
Abstract We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254). Patients with metastatic cancer underwent tumor profiling and were ran
Externí odkaz:
https://doaj.org/article/0dcfdec9f8b24bf8a8a6b4c9cca14e08
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and insoluble fibrils. BAN2401-G000-201, a randomized double-blind clini
Externí odkaz:
https://doaj.org/article/edd30e11757844c3a76924e96d5411df
Autor:
Apostolia Maria Tsimberidou, David S. Hong, Siqing Fu, Daniel D. Karp, Sarina Piha-Paul, Merrill S. Kies, Vinod Ravi, Vivek Subbiah, Sunil M. Patel, Shi-Ming Tu, Filip Janku, John Heymach, Amber Johnson, Carrie Cartwright, Li Zhao, Jianhua Zhang, Donald A. Berry, David J. Vining, Andrew Futreal, Vincent A. Miller, Funda Meric-Bernstam
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-9 (2021)
Abstract Precision medicine is associated with favorable outcomes in selected patients with cancer. Herein, we report an interim analysis of IMPACT2, an ongoing randomized study evaluating genomic profiling and targeted agents in metastatic cancer. P
Externí odkaz:
https://doaj.org/article/33315794ca1f4daf8eba5da8574c8e3f
Autor:
Donald A Berry, Andrew Ip, Brett E Lewis, Scott M Berry, Nicholas S Berry, Mary MrKulic, Virginia Gadalla, Burcu Sat, Kristen Wright, Michelle Serna, Rashmi Unawane, Katerina Trpeski, Michael Koropsak, Puneet Kaur, Zachary Sica, Andrew McConnell, Urszula Bednarz, Michael Marafelias, Andre H Goy, Andrew L Pecora, Ihor S Sawczuk, Stuart L Goldberg
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0255228 (2021)
ObjectivesThe development of a prognostic mortality risk model for hospitalized COVID-19 patients may facilitate patient treatment planning, comparisons of therapeutic strategies, and public health preparations.MethodsWe retrospectively reviewed the
Externí odkaz:
https://doaj.org/article/0544c34f8de74d10831452a6e428d4c2
Autor:
Chad J. Swanson, Yong Zhang, Shobha Dhadda, Jinping Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, Heather Bradley, Martin Rabe, Akihiko Koyama, Larisa Reyderman, Donald A. Berry, Scott Berry, Robert Gordon, Lynn D. Kramer, Jeffrey L. Cummings
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/9e3c60d518ed4e89a11178d614b7e937
Autor:
Donald A Berry, Scott Berry, Peter Hale, Leah Isakov, Andrew W Lo, Kien Wei Siah, Chi Heem Wong
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0244418 (2020)
We compare and contrast the expected duration and number of infections and deaths averted among several designs for clinical trials of COVID-19 vaccine candidates, including traditional and adaptive randomized clinical trials and human challenge tria
Externí odkaz:
https://doaj.org/article/30e6ac668198414a8c970e0215f9ac9b